Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shailender Bhatia

Showing results (51-60 of 123) with videos related to

Pageof 13
Sort By:
International Journal of Particle Therapy|November 28, 2019
Neutron Radiation Therapy for Treatment of Refractory Merkel Cell CarcinomaMeghan W Macomber, Erica S Tarabadkar, Nina A Mayr, et al.
Journal of the American Academy of Dermatology|July 25, 2020
Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patientsNeha Singh, Nora A Alexander, Kristina Lachance, et al.
International Journal of Radiation Oncology, Biology, Physics|September 8, 2018
Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell CarcinomaYolanda D Tseng, Macklin H Nguyen, Kelsey Baker, et al.
The Journal of Investigative Dermatology|November 30, 2012
Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stageKelly G Paulson, Jayasri G Iyer, Astrid Blom, et al.
Journal for Immunotherapy of Cancer|September 19, 2025
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trialsPeter Y Ch'en, Yuzheng Zhang, Daniel S Hippe, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographicsKelly G Paulson, Song Youn Park, Natalie A Vandeven, et al.
The Oncologist|July 7, 2025
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)Wenwen Chen, Julia Majovski, Shailender Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinomaJohn A Thompson, Brendan D Curti, Bruce G Redman, et al.
Journal for Immunotherapy of Cancer|December 25, 2025
Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanomaMelissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2012
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeAude G Chapuis, John A Thompson, Kim A Margolin, et al.
Pageof 13

Showing results (51-60 of 123) with videos related to

Sort By:
Pageof 13
International Journal of Particle Therapy|November 28, 2019
Neutron Radiation Therapy for Treatment of Refractory Merkel Cell CarcinomaMeghan W Macomber, Erica S Tarabadkar, Nina A Mayr, et al.
Journal of the American Academy of Dermatology|July 25, 2020
Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patientsNeha Singh, Nora A Alexander, Kristina Lachance, et al.
International Journal of Radiation Oncology, Biology, Physics|September 8, 2018
Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell CarcinomaYolanda D Tseng, Macklin H Nguyen, Kelsey Baker, et al.
The Journal of Investigative Dermatology|November 30, 2012
Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stageKelly G Paulson, Jayasri G Iyer, Astrid Blom, et al.
Journal for Immunotherapy of Cancer|September 19, 2025
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trialsPeter Y Ch'en, Yuzheng Zhang, Daniel S Hippe, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographicsKelly G Paulson, Song Youn Park, Natalie A Vandeven, et al.
The Oncologist|July 7, 2025
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)Wenwen Chen, Julia Majovski, Shailender Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinomaJohn A Thompson, Brendan D Curti, Bruce G Redman, et al.
Journal for Immunotherapy of Cancer|December 25, 2025
Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanomaMelissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2012
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeAude G Chapuis, John A Thompson, Kim A Margolin, et al.
Pageof 13